Michael Dennis Connolly

US Patent:

6875765, Apr 5, 2005

Filed:

May 10, 2002

Appl. No.:

10/143675

Inventors:

James Knobelsdorf - Knoblesville IN, US
Sheryl Hays - Ann Arbor MI, US
Charles J. Stankovic - Saline MI, US
Kimberly S. Para - Ann Arbor MI, US
Michael K. Connolly - Ypsilanti MI, US
Paul Galatsis - Ann Arbor MI, US
William Harter - Chelsea MI, US
Aurash B. Shahripour - Ann Arbor MI, US
Mark Stephen Plummer - Dexter MI, US
Beth Lunney - San Diego CA, US
Bernd Janssen - Marlborough MA, US
Jay Bradford Fell - Longmont CO, US

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

C07D295/14
C07D407/12
C07D487/04
A61K031/495
A61P019/02

US Classification:

5142382, 51425212, 514303, 514311, 514312, 514307, 514331, 514365, 514368, 514394, 514400, 514405, 514562, 544159, 544399, 546118, 546149, 546157, 546172, 546235, 548154, 548204, 5483087, 5483097, 5483385, 5483625, 562430

Abstract:

The novel arylsulfonamide ether compounds, pharmaceutical compositions and uses thereof as inhibitors of interleukin-1β converting enzyme and other cysteine proteases in the ICE family are described. In one embodiment, the compound is described by the generalized structure: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis, using a compound of the invention or a pharmaceutical composition thereof, are described.

US Patent:

8053485, Nov 8, 2011

Filed:

Nov 5, 2008

Appl. No.:

12/265487

Inventors:

Hanna Lekovic - Troy MI, US
Frank Hoefflin - Royal Oak MI, US
Michael Anderson - Oxford MI, US
Trent Shidaker - The Woodlands TX, US
Michael Connolly - Ypsilanti MI, US
Sheila Dubs - Conroe TX, US
Jinhuang Wu - Troy MI, US

Assignee:

Sika Technology AG - Baar

International Classification:

C08G 18/28

US Classification:

521130, 521163, 521164, 521167, 521170, 521174, 521175, 521176

Abstract:

A polyurethane foam is disclosed and described. The polyurethane foam is formed by combining a first component comprising at least one polyol with a second component comprising at least one polyisocyanate. The ratio of the number of isocyanate equivalents in the second component to the number of hydroxyl equivalents in the second component is less than 1. The foam exhibits low levels of free diisocyanate monomer, thereby reducing the amount of hazardous, volatile organic compounds. As a result, the foam can be prepared and installed without the need for ventilation equipment, external sources of fresh air, and the like.

US Patent:

8372893, Feb 12, 2013

Filed:

Sep 23, 2011

Appl. No.:

13/243826

Inventors:

Hanna Lekovic - Troy MI, US
Frank Hoefflin - Royal Oak MI, US
Michael Anderson - Oxford MI, US
Trent Shidaker - The Woodlands TX, US
Michael Connolly - Ypsilanti MI, US
Sheila Dubs - Conroe TX, US
Jinhuang Wu - Troy MI, US

Assignee:

Sika Technology AG - Baar

International Classification:

C08G 18/28

US Classification:

521174, 521130, 521163, 521164, 521167, 521170, 521175, 521176, 4284231, 4284258

Abstract:

This disclosure describes a method of making a polyurethane foam and a method of reducing NVH expected to be experienced by a substrate using the foam. When the foam is subjected to 95% relative humidity for a period of 7 days at a temperature of about 50 C. , the foam absorbs an amount of water that is less than about 30% of the weight of the foam.

US Patent:

20040259926, Dec 23, 2004

Filed:

Jun 3, 2004

Appl. No.:

10/860348

Inventors:

Michelle Bruendl - Ann Arbor MI, US
Michael Connolly - Ypsilanti MI, US
Annise Goodman - West Bloomfield MI, US
Rocco Gogliotti - Pinckney MI, US
Helen Lee - Ann Arbor MI, US
Mark Plummer - Dexter MI, US
Karen Sexton - Chelsea MI, US
Aurash Shahripour - Ann Arbor MI, US
Greg Reichard - Ann Arbor MI, US
Melean Visnick - Ann Arbor MI, US
Michael Wilson - Ann Arbor MI, US

International Classification:

A61K031/41
C 07D 4 9/02

US Classification:

514/381000, 548/251000

Abstract:

The present invention provides benzo[b]thiophenes of Formula I: wherein R, R, R, R, R, and L have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

US Patent:

20050020630, Jan 27, 2005

Filed:

Jun 3, 2004

Appl. No.:

10/860524

Inventors:

Michael Connolly - Ypsilanti MI, US
Rocco Gogliotti - Pinckney MI, US
Helen Lee - Ann Arbor MI, US
Mark Plummer - Dexter MI, US
Karen Sexton - Chelsea MI, US
Melean Visnick - Ann Arbor MI, US

International Classification:

C 07D 4 9/14
A61K031/454
A61K031/41

US Classification:

514320000, 514381000, 546196000, 548251000

Abstract:

The present invention provides benzo[b]thiophenes of Formula I: wherein R, R, R, and L have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

US Patent:

20050096350, May 5, 2005

Filed:

Sep 7, 2004

Appl. No.:

10/935356

Inventors:

Michael Connolly - Ypsilanti MI, US
Rocco Gogliotti - Pinckney MI, US
Clarence Hurt - San Ramon CA, US
Gregory Reichard - Ann Arbor MI, US
Melean Visnick - Ann Arbor MI, US

International Classification:

C07D049/14
A61K031/454
A61K031/41

US Classification:

514320000, 514381000, 546202000, 548253000

Abstract:

The present invention provides benzo[b]thiophenes of Formula I: wherein R, R, R, R, R, Y, and L have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

US Patent:

20060173128, Aug 3, 2006

Filed:

Mar 29, 2006

Appl. No.:

11/392345

Inventors:

Michael Connolly - Ypsilanti MI, US

Assignee:

Huntsman International LLC - The Woodlands TX

International Classification:

C08G 18/08
B29C 67/00

US Classification:

524589000, 264136000

Abstract:

Polyisocyanate-based reaction systems, a pultrusion process employing those systems to produce reinforced matrix composites, and to composites produced thereby. The polyisocyanate-based systems are mixing activated reaction systems that include a polyol composition, a catalyst composition which comprises a combination of at least two different metals in effective amounts, an optional chain extender or crosslinker, and a polyisocyanate. The polyisocyanate-based systems facilitate the practical use of higher line speeds in the manufacture of fiber reinforced thermoset composites via reactive pultrusion.

US Patent:

20090227587, Sep 10, 2009

Filed:

Oct 19, 2004

Appl. No.:

11/664975

Inventors:

Michael Kevin Connolly - Ypsilanti MI, US
Rocco Dean Gogliotti - Pinckney MI, US
Mark Stephen Plummer - Dexter MI, US
Melean Visnick - Ann Arbor MI, US

International Classification:

A61K 31/5377
C07D 413/14

US Classification:

5142365, 544122

Abstract:

The present invention provides pyrimidines of Formula I:wherein R, R, and Y have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.